CT-173 / Roche - LARVOL DELTA

Roche axes Carmot obesity asset, 3 cancer drugs in R&D clear-out (FierceBiotech) - "Roche has axed one of the obesity assets from its $2.7 billion Carmot Therapeutics buyout, sending the molecule to the scrap heap months after hyping its potential to drive weight loss past the GLP-1 plateau. The drugmaker disclosed the action alongside news of a cull of early-phase solid tumor programs....The dropped obesity candidate, CT-173, is a long-acting PYY analog. Roche was planning (PDF) to start a phase 1 trial of the molecule this year. However, the Swiss drugmaker has decided to stop development before entering the clinic. Roche disclosed (PDF) the decision as part of its financial results for the second quarter."

Discontinued • Obesity